GlobalData on MSN21h
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
Daily14h
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
Medpage Today on MSN2d
FDA OKs New Option for Rare Immune-Mediated Vasculitis
The FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with ...
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Monthly Prescribing Reference10d
MATINEE: Mepolizumab Significantly Reduces COPD Exacerbations
The randomized, double-blind, placebo-controlled phase 3 MATINEE study evaluated the safety and efficacy of mepolizumab in patients with COPD and type 2 inflammation.
Medscape1d
FDA Approves Benralizumab for EGPA Vasculitis Indication
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
copdnewstoday3d
Mepolizumab reduces exacerbations in COPD with type 2 inflammation
Adding GSK’s mepolizumab to standard inhaled treatment for COPD reduces the frequency of exacerbations in patients with type ...
Managed Healthcare Executive1d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
AstraZeneca: Fasenra Approved By FDA To Treat Eosinophilic Granulomatosis With Polyangiitis
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...
pulmonologyadvisor1d
FDA Approves Fasenra for Eosinophilic Granulomatosis With Polyangiitis
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.